Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer

BACKGROUND: Bisphosphonates (BPs) including zoledronate (zol) have become standard care for bone metastases as they effectively inhibit tumor-induced osteolysis and associated pain. Several studies have also suggested that zol has direct anti-tumor activity. Systemic administration at high doses is...

Descripción completa

Detalles Bibliográficos
Autores principales: Akoury, Elie, Ahangar, Pouyan, Nour, Antone, Lapointe, Jacques, Guérard, Karl-Philippe, Haglund, Lisbet, Rosenzweig, Derek H., Weber, Michael H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368819/
https://www.ncbi.nlm.nih.gov/pubmed/30787671
http://dx.doi.org/10.1186/s12935-019-0745-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368819/
https://www.ncbi.nlm.nih.gov/pubmed/30787671
http://dx.doi.org/10.1186/s12935-019-0745-x

Ejemplares similares